cetrorelix


Also found in: Wikipedia.

cetrorelix

 [set″ro-rel´iks]
a gonadotropin-releasing hormone antagonist, used to inhibit premature luteinizing hormone surges in women undergoing controlled ovarian stimulation during infertility treatment; administered subcutaneously.
References in periodicals archive ?
GnRH Antagonist (0.25 mg cetrorelix acetate, Cetrotide, Serono) was added when the diameter of follicle reached 12 mm.
Delayed start protocol was defined as administration of cetrorelix acetate (Cetrotide[R], Injection, Powder, 250 [micro]g, Serpero pharmaceutical, Italy) as a GnRH antagonist at a dose of 250 [micro]g per night on cycle day two to seven, and those in the control group underwent standard COS by GnRH antagonist protocol with estradiol priming.
Controlled ovarian hyperstimulation (COH) was initiated on the third day of the menstrual cycle with high dose recombinant FSH (rFSH, Gonal F, Merck Serono, Rome, Italy) and GnRH antagonist (cetrorelix, Cetrotide, Baxter Oncology GmbH, Frankfurt, Germany) to prevent premature ovulation.
GnRHant (Cetrorelix, Merck Serono, France) dissolved in sterilized distilled water was injected at a dose of 0.1mg/kg 1 hour prior to the CPA injection and continued for 4 weeks (3 times a week).
In Group A patients, when the leading follicle reached a size of 14 mm, GnRH antagonist Cetrorelix was added and continued along with HMG daily till the day of h CG.
For example, NMBR genetargeted drugs included Bombesin and Ranatensin; GNRHR was the target of Degarelix, Nafarelin, Cetrorelix, Goserelin, and Leuprolide; F2RL3 gene was related to Argatroban.
The treatment was carried out with GnRH antagonist downregulated protocol using cetrorelix (Cetrotide; Merck Serono, UK).
In the antagonist protocol, the gonadotropin was started on CD 3 and 0.25 mg cetrorelix (Cetrotide; Asta Medica, Frankfurt, Germany) was administered daily when two or more follicles reached 13-14 mm in diameter.
When the leading follicle reached the size of 14 mm and/or the levels of estradiol reached the value >300 pg/mL, a daily injection of cetrorelix 0.25 mg (Cetrotide; Merc Serono, Switzerland) was included.
Animals from groups C (cetrorelix) were administered cetrorelix acetate (ChemPep, Inc., Wellington, USA).
GnRH antagonist fixed protocol included direct gonadotropin suppression via the subcutaneous administration of cetrorelix acetate (Cetrotide 0.25mg(R); Merck Serono) 0.25mg/day on 6th day of the menstrual cycle.